- Cowen 40 th Annual Health Care Conference on March 2 nd-4 th in Boston, MA
- Roth Capital 32 nd Annual Conference on March 16 th-17 th in Laguna Niguel, CA
NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two upcoming investor conferences in March 2020.
Raj Mehra, Ph.D., Chairman and CEO, will present at the Cowen 40 th Annual Health Care Conference on Wednesday, March 4 th at 8:40am ET.
The live audio webcast of the presentation can be accessed at: http://wsw.com/webcast/cowen57/seel/
Please note that this replay will be available for 90 days following the presentation.
Dr. Mehra will also participate at the Roth Capital 32 nd Annual Conference and present on Tuesday, March 17 th at 8:00am PT.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.
Anthony Marciano Head of Corporate Communications Seelos Therapeutics, Inc. (Nasdaq: SEEL) 300 Park Ave., 12th Fl New York, NY 10022 (646) 293-2136 email@example.com https://seelostherapeutics.com/ https://twitter.com/seelostx https://www.linkedin.com/company/seelos